Impact of COVID-19 on Economy, Industry and Company :
The emergence of novel coronavirus has affected the global economy, industry dynamics and company’s top line. The entire ecosystem has to suffer the impact of this pandemic disease which would result in significant demand & supply gap, production delay and weak consumer demand of end products across industries. At Bizizz Market Research, our analyst has done extensive research across industries and identify various methodologies which would assist C-Level executive to counter this ongoing threat and make informed business decision.
Kindly contact us to know more details: https://www.bizizzmarketresearch.com/contact
The Neuropathic Pain market registered USD 5.5 Billion in 2018 and it is estimated to reach more than USD 10.6 Billion by 2024, likely to grow with a CAGR of 7.6 % during the forecast period
Neuropathic pain is a state of persistent aching that is instigated by a primary laceration like infection, trauma or other debilitation in the nervous system. Well-known disorders of neuropathic pain include complex regional pain syndrome, central pain syndromes, postsurgical pain syndromes, painful polyneuropathy, painful traumatic mononeuropathy, postherpetic neuralgia, and root avulsions. Some of the usual prescriptions recommended for neuropathic pain are antidepressants (or tricyclic antidepressants), anesthetics, and anticonvulsants (also infection known as neuroleptic medications). Clonazepam, carbamazepine, phenytoin, Valproic acid, felbamate are the most common anticonvulsants used for the treatment of neuropathic disorders. Additionally, nortriptyline and amitriptyline are the most frequently used antidepressants.
Neuropathy pain takes place as a result of the injuries in the peripheral nerves. Neuropathy pain generates sensations like sharp pins and needles, burning pains, and numbness that can intensify at night. In recent times, the number of people diseased by some peripheral neuropathy has been increasing constantly, which is resulting in the rising adoption of treatment techniques for neuropathic pain and expected to boost the growth of the global market in the coming future.
The Growing Requisition for Superior Treatment Techniques for Neuropathic Pain is Optimistically Estimated to Boost the Evolution of the International Neuropathic Pain Market
There are a number of treatments and medications accessible in the market to encounter the surpassing demand for managing the disorder. The boosting demand for effectual therapies headed by the growing number of the patient population largely powers the growth of the neuropathic pain market. Besides, the accessibility of many distinctive treatment procedures and practices is accelerating the market on the international platform.
The growing number of diabetes and cancer circumstances act as a substantial impulse pushing up the market growth, initiating the peripheral nerve impairment. Furthermore, facets like the increasing demand for generic drugs to relieve pain levels, escalation of pain management centers and, provide provocation to the growth of the neuropathic pain market. Additionally, medicinal establishments are vigorously converging on developing superior medicines to supply to the necessity of patients with neuropathic disorders.
Contrariwise, aspects specifically the shortage of consciousness concerning the disorder and the efficient techniques to accomplish the same along with the escalating expenditure of therapy hinder the market progress particularly in developing regions. Nonetheless, scientific development and the accumulative number of ambulatory facilities are likely to benefit the growth of the neuropathic pain market, making the treatment reasonably priced for all.
Anticonvulsants Medicine is estimated to be the Prominent Fragment of the Neuropathic Pain Market
Anticonvulsants medication is expected to be the predominant fragment of the neuropathic pain market. The lowest threat of side effects is a primary factor boosting the demand for the anticonvulsants drug segment. Moreover, rising consciousness about the anticonvulsants that are accessible in the market is helping the growth of the Anticonvulsants drug segment.
North America is anticipated to be the Dominant Region, Accounted for 36.12% share in 2019
The North American region, leading with the massive progress in technology explicitly micro-particle treatment and its initial implementation in formulizing in therapeutic cannabis accounts for the prominent market in the international neuropathic pain market. Factors such as the accessibility of a range of pain management products and promising government strategies are nurturing the growth of the neuropathic pain market. Moreover, other aspects like the rising patient pool are expected to drive the development of the Neuropathic Pain market in North America, stimulating efficient treatment techniques and operations.
The neuropathic pain market in the European region holds the second-largest market share, internationally. Facets fast-moving up the evolution of the European neuropathic pain market embrace the escalation in the ailment that has directed to a growing number of casualties and the well-proliferated healthcare segment.
The neuropathic pain market in the Asia Pacific region is speedily evolving as a favourable market, worldwide. China, sponsored by the massive high-tech evolution in the therapeutic devices industry heads the regional market. Furthermore, India stands second in terms of the market size, trailed by Australia and Japan. Facets specifically the presence of a huge patient population, increasing consciousness about the disorder and the accessibility of treatment techniques are some of the driving forces that are fuelling the market in the region.
Ferociously competitive the neuropathic pain market seems to be split with the manifestation of several big and small companies. These players integrate premeditated ingenuities such as expansion, product & technology launch, partnership, collaboration, merger, and acquisition to advance an upper hand over their contenders. They considerably capitalize on R&D programs to improve technology and medical instruments beneficial in the treatment of the pain. Vast government finance is also anticipated to stimulate leading corporations to cultivate progressive innovative treatments.
Major establishments functioning in the international market for neuropathic pain comprise Eli Lily and Company, Johnson & Johnson Services, Inc., Biogen Idec, Pfizer, Inc., Baxter Healthcare Corporation Sanofi S.A., GlaxoSmithKline PLC, Bristol Myers Squibb and Depomed, Inc.
Most of these medicinal corporations are aggressively concentrating on developing superior medicine for the treatment of neuropathic pain and other ailments in order to strengthen their presence in the international market for neuropathic pain.
Global Neuropathic Pain Market, By Type
- Peripheral Neuropathy
- Entrapment Neuropathy
- Phantom Limb Pain
- Trigeminal Neuralgia
- Post Herpetic Neuralgia
- Post Traumatic Neuropathy
Global Neuropathic Pain Market, By Indication
- Diabetic Neuropathy
- Chemotherapy-Induced Peripheral Neuropathy
- Spinal Stenosis
Global Neuropathic Pain Market, By Diagnosis
- Physical Examination
- Blood Tests
Global Neuropathic Pain Market, By Treatment
- Multimodal Therapy
Global Neuropathic Pain Market, By Distribution Channel
- Online Pharmacies
- Retail Pharmacies
- Drug Stores
Global Neuropathic Pain Market, By End-User
- Research Organizations
Global Neuropathic Pain Market, By Region
- North America
- Asia Pacific
- Middle East & Africa
- South America